Navigation Links
MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone

nts with aggressive NHL," said William M. Burns, CEO Division Roche Pharma. "Seven years after the GELA trial, over half of the MabThera patients are still alive, offering hope of a cure for thousands more."

Non-Hodgkin's lymphoma (NHL) affects 1 million people worldwide. It is estimated that 360,000 people die each year from the disease (2). Approximately 40% of NHL patients present with an aggressive form of the disease, which, if left untreated, is generally fatal within six months.

About the study The study was conducted at 86 centers in France, Belgium, and Switzerland. A total of 398 patients were enrolled between July 1998 and March 2000. Previously untreated patients with diffuse large-B-cell lymphoma, 60 to 80 years old, were randomly assigned to receive either eight cycles of CHOP every three weeks (197 patients) or eight cycles of CHOP plus rituximab given on day 1 of each cycle (202 patients). The primary end point in this study was event-free survival.

About MabThera MabThera is a therapeutic antibody that binds to a particular protein - the CD20 antigen - on the surface of normal and malignant B-cells. It then recruits the body's natural defences to attack and kill the marked B-cells. Stem cells (B-cell progenitors) in bone marrow lack the CD20 antigen, allowing healthy B-cells to regenerate after treatment and return to normal levels within several months.

MabThera is indicated for the treatment of indolent and aggressive Non-Hodgkin's Lymphoma. MabThera is known as Rituxan in the United States, Japan and Canada. To date, patients have received more than 1 million treatments with MabThera worldwide.

Genentech and Biogen Idec co-market MabThera in the United States, and Roche markets MabThera in the rest of the world, except Japan, where MabThera is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd.

About Roche Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare gr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
2. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
(Date:9/30/2014)... Fat Burning Kitchen , the latest diet guide ... that is helping people learn the truth about so-called health ... in less than 24 hours has caught the attention of ... culture that is becoming so obsessed with diets and weight ... fact and fiction when it comes to health foods, eating ...
(Date:9/30/2014)... White Plains, NY (PRWEB) September 30, 2014 ... (HPCW) recently hosted its annual “In Celebration” gala, ... furthering the nonprofit’s mission of striving to provide ... individuals and families facing a serious or life-limiting ... Westchester Country Club in Rye, NY and recognized ...
(Date:9/30/2014)... 30, 2014 Two revolutionary procedures now being ... of gum disease a far less painful and far ... “If you’ve ever felt electric shock waves surge through your ... cold beverage, it’s possible you already know the impact of ... a general dentist in West Palm Beach, and a Fellow ...
(Date:9/30/2014)... An unprecedented, public-private partnership funded by the Department ... the development of better-run clinical trials and may ... brain injury, a condition affecting not only athletes ... public, ranging from youngsters to elders. , ... with a $17 million, five-year award from the ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 Healthpointe ... is now performing advanced foot and ankle reconstruction surgeries ... board-certified orthopedic surgeon, Dr. Cortés specializes in the diagnosis ... ankle injuries . She is also trained to perform ... their orthopedic needs. Dr. Cortés is also fluent in ...
Breaking Medicine News(10 mins):Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:US aims for traumatic brain injury clinical trial success 2Health News:US aims for traumatic brain injury clinical trial success 3Health News:US aims for traumatic brain injury clinical trial success 4Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3
... Applications in Healthcare (C-PAHC) Now Accepting ... ... Records Institute introduces,today the Center for Cell Phone Applications in Healthcare ... phone applications in healthcare., (Logo: http://www.newscom.com/cgi-bin/prnh/20080825/NEM092LOGO ), ...
... best available option for people with hemochromatosis , , ... dismissed as a primitive form of medicine, in which ... humors by draining the life-sustaining fluid. , But there,s ... the preferred means of treatment. , Hemochromatosis is an ...
... invivodata to 2008 Pittsburgh 100, PITTSBURGH, Aug. ... patient reported outcomes (ePRO) solutions and,services for global ... has recognized the company in the "2008 Pittsburgh ... Western,Pennsylvania., "We see the Pittsburgh 100 as ...
... avoidance strategies , , MONDAY, Aug. 25 (HealthDay News) -- ... to ensure the safety of the more than 2.2 ... Academy of Allergy, Asthma & Immunology. , "Open and ... key ingredient to keeping food-allergic students out of harm. ...
... YORK, Aug. 25 HMS Holdings Corp. (Nasdaq:,HMSY) today ... Partners,2008 Healthcare Conference, which will be held September 3-5, ... Walter Hosp, SVP and Chief Financial Officer of HMS ... pm Eastern Time., A live broadcast of the ...
... 25 Dr. Anthony Ohotto, a physician,with Signature Hospice, ... "Limited life expectancy is no reason not to do ... the order as a health clearance, a,statement that the ... The Hospice team members at Signature Hospice had noted ...
Cached Medicine News:Health News:Medical Records Institute Unveils Platform for Studying Cell Phone Applications in Healthcare 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:invivodata Recognized as One of Pittsburgh's Fastest Growing Private Companies 2Health News:Food Allergy Action Plan Can Keep Kids From Harm 2Health News:Signature Hospice Team Grants Patient's Unusual Wish 2
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Straight shafts with 15 mm long jaws. Serrated handle with polished finish. Smooth jaws....
Straight shafts with 6.5 mm tying platform. Crisscross serrated 1mm tips. Scalloped handle with dull finish....
Smooth tip forceps allow the surgeon to manipulate and smooth the corneal flap in Lasik procedures. Tip angled 10 mm from tip. Manufactured in titanium....
Medicine Products: